ImageneBio (IMA) CFO Jotin Marango to step down on Oct. 20, 2025

Rhea-AI Filing Summary

ImageneBio, Inc. reported that its Chief Financial Officer and principal financial officer, Jotin Marango, M.D., Ph.D., has submitted his resignation, effective October 20, 2025. The company states that his resignation is not due to any disagreement with the company. ImageneBio plans to conduct a search for a new chief financial officer to fill the role.

Insights

Corporate governance analyst

ImageneBio’s CFO is resigning, with no stated disagreement and a search planned for a successor.

The company reports that Chief Financial Officer and principal financial officer Jotin Marango, M.D., Ph.D., has resigned effective October 20, 2025. It explicitly notes that his departure is not due to any disagreement with the company, which limits the signal of internal conflict or dispute based on this disclosure alone.

Leadership transitions in the finance function can affect continuity in financial reporting and capital planning, but the filing keeps the focus on the fact of the resignation and timing. ImageneBio indicates it plans to conduct a search for a replacement, suggesting an intent to fill the role rather than restructuring away from it. The overall impact depends on the future appointment and how quickly the company completes the transition.

NASDAQ false 0001835579 0001835579 2025-10-10 2025-10-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 10, 2025, Jotin Marango, M.D., Ph.D., our Chief Financial Officer and principal financial officer, provided notice of his resignation, effective October 20, 2025. Dr. Marango’s resignation was not due to any disagreement with the Company. We plan to conduct a search for Dr. Marango’s replacement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: October 10, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What leadership change did IMAGENEBIO, INC. (IMA) disclose in this 8-K?

The company disclosed that Chief Financial Officer and principal financial officer Jotin Marango, M.D., Ph.D., has resigned, with an effective date of October 20, 2025.

Did ImageneBio (IMA) indicate any disagreements related to the CFO’s resignation?

ImageneBio stated that Dr. Marango’s resignation was not due to any disagreement with the company.

When does ImageneBio’s CFO resignation become effective?

The resignation of Jotin Marango, M.D., Ph.D. as Chief Financial Officer and principal financial officer is effective on October 20, 2025.

What are ImageneBio’s plans to replace its departing CFO?

The company states that it plans to conduct a search for a replacement for Dr. Marango as Chief Financial Officer.

What position does Kristin Yarema hold at ImageneBio (IMA)?

Kristin Yarema, Ph.D., signed the report on behalf of ImageneBio in her capacity as Chief Executive Officer.